SciELO - Scientific Electronic Library Online

 
vol.33 número3Bupropión: una alternativa farmacológica en cesación tabáquicaTerapia combinada para el control de la dependencia a nicotina índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista chilena de enfermedades respiratorias

versión On-line ISSN 0717-7348

Resumen

PENA G., Pedro  y  ZAGOLIN B., Mónica. Varenicline. Rev. chil. enferm. respir. [online]. 2017, vol.33, n.3, pp.212-215. ISSN 0717-7348.  http://dx.doi.org/10.4067/s0717-73482017000300212.

Varenicline is a first-line therapy cessation of smoking, and has the highest effectiveness widely demonstrated in clinical trials with drop-out figures per year of the order of 25-35%. In the most recent effectiveness review conducted by the Cochrane, 39 trials were evaluated that randomized varenicline versus placebo and compared with nicotine substitutes (NRT) and bupropion. With varenicline, a RR of 2.24 was observed for abstinence at 6 months or longer at standard doses (2 mg daily) versus placebo. The RR of varenicline versus placebo compared with bupropion or NRT was 1.3 and 1.25 respectively showing its superiority once again. When the use of varenicline was evaluated for a period longer than 12 weeks, it was observed that the drug was well tolerated suggesting that its use is feasible without intensifying the adverse effects.

Palabras clave : Smoking cessation; nicotinic antagonists; varenicline; bupropion; nicotine.

        · resumen en Español     · texto en Español     · Español ( pdf )